The Academy of Managed Care Pharmacy hosted a multi-stakeholder meeting last week in Baltimore at which attendees discussed some payment models health care payers could incorporate as high-cost treatments enter the market each year.
The AMCP Partnership Forum, titled “Designing benefits and Payment Models for Innovative, High-Investment Medications,” welcomed more than 30 experts representing “health plans, integrated delivery systems, pharmacy benefit managers, employers, national professional associations, the federal government and biopharmaceutical companies.”
“The pace of biopharmaceutical innovation is rapidly bringing to reality the promise of cures or ‘near-cures’ to many long-intractable diseases,” AMCP CEO Susan Cantrell said. “While this is great news for society, the challenge for payers is how to ensure broad coverage for these products in an era of constrained budgets. That challenge is compounded by the dynamic nature of our insurance system, in which patients may switch among carriers before the full effects of a therapy are realized.”
Stakeholders looked at a range of solutions, according to a press release, including long-term annuity payments, reinsurance markets, performance-based payments and milestone contracting.
To read the full press release on PR Newswire, click here.
